Sarepta Therapeutics
(NQ:
SRPT
)
122.41
+4.42 (+3.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
10 Health Care Stocks Whale Activity In Today's Session
June 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Expert Ratings for Sarepta Therapeutics
May 19, 2022
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Via
Benzinga
Sarepta Therapeutics: Q1 Earnings Insights
May 04, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership
February 01, 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to
Via
Benzinga
Analyst Ratings For Sarepta Therapeutics
January 18, 2022
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:
Via
Benzinga
Sarepta Therapeutics's Earnings: A Preview
May 03, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Expert Ratings For Sarepta Therapeutics
December 09, 2021
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed th...
Via
Benzinga
Analyst Ratings For Sarepta Therapeutics
November 04, 2021
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...
Via
Benzinga
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
April 07, 2022
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.
Via
Investor's Business Daily
Tough Slogging Ahead for Investors, Diversification is Important
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Where Sarepta Therapeutics Stands With Analysts
March 02, 2022
Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
March 01, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Sarepta Therapeutics's Earnings Outlook
February 28, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 14, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate
January 13, 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on...
Via
Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
January 05, 2022
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
Upgrades For IGM Biosciences Inc (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
November 04, 2021
The biotech stock fell a little more than $72 since its close last Friday.
Via
The Motley Fool
Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript
November 04, 2021
SRPT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Earnings Scheduled For November 3, 2021
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.